Hubei Goto BiopharmLtd Past Earnings Performance
Past criteria checks 0/6
Hubei Goto BiopharmLtd's earnings have been declining at an average annual rate of -28%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 0.3% per year. Hubei Goto BiopharmLtd's return on equity is 2%, and it has net margins of 4%.
Key information
-28.0%
Earnings growth rate
-36.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -0.3% |
| Return on equity | 2.0% |
| Net Margin | 4.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Hubei Goto BiopharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 569 | 23 | 54 | 37 |
| 31 Dec 23 | 566 | 23 | 51 | 38 |
| 30 Sep 23 | 543 | 23 | 54 | 46 |
| 30 Jun 23 | 604 | 31 | 50 | 49 |
| 31 Mar 23 | 604 | 31 | 49 | 47 |
| 31 Dec 22 | 605 | 40 | 47 | 45 |
| 30 Sep 22 | 592 | 64 | 39 | 42 |
| 30 Jun 22 | 557 | 64 | 41 | 41 |
| 31 Mar 22 | 570 | 76 | 41 | 39 |
| 01 Jan 22 | 591 | 78 | 41 | 37 |
| 30 Sep 21 | 595 | 76 | 36 | 35 |
| 30 Jun 21 | 569 | 76 | 29 | 28 |
| 31 Mar 21 | 573 | 71 | 27 | 26 |
| 31 Dec 20 | 468 | 53 | 21 | 22 |
| 31 Dec 19 | 465 | 73 | 23 | 26 |
| 31 Dec 18 | 437 | 71 | 17 | 27 |
| 31 Dec 17 | 334 | 47 | 19 | 23 |
Quality Earnings: 300966 has a large one-off loss of CN¥8.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300966's current net profit margins (4%) are lower than last year (5.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300966's earnings have declined by 28% per year over the past 5 years.
Accelerating Growth: 300966's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300966 had negative earnings growth (-27.7%) over the past year, making it difficult to compare to the Biotechs industry average (-3.2%).
Return on Equity
High ROE: 300966's Return on Equity (2%) is considered low.